Cationic arene ruthenium(ii) complexes with chelating P-functionalized alkyl phenyl sulfide and sulfoxide ligands as potent anticancer agents

Abstract

The synthesis and characterization of cationic ruthenium(II) complexes of the type [Ru(η(6)-p-cym)Cl{Ph(2)P(CH(2))(n)S(O)(x)Ph-κP,κS}][PF(6)] (n = 1-3; x = 0, 1; p-cym = p-cymene) are presented. Furthermore, their high biological potential even against cisplatin-resistant tumor cell lines and their structure-activity relationships are discussed.

Ruthenium complex Λ-WH0402 induces hepatocellular carcinoma LM6 (HCCLM6) cell death by triggering the Beclin-1-dependent autophagy pathway

“…Ruthenium belongs to the same group of elements as iron, which is reflected by its strong affinity for transferrin and by the necessity of its reductive activation in cells. Now, ruthenium complexes show not only good cytotoxic activity, but also remarkable antitumoral and antimetastatic activities 5,14 and have been widely developed as alternatives to platinum chemotherapeutics. 13 Ruthenium III complexes are likely to be activated by reduction to Ru II in the body.…”

Interacción de ARN con doxorrubicina: Influencia del ligando y del metal en la actividad biológica de complejos organometálicos

“…Previous works have studied the relation structure-activity of Iridium(III) families compounds varying the quelating substituents [134], in combination with monodentate ligands [135] and bidentate C,N- [136], N,N- [137,138], N,O- [139], P,O- [140], P,P- [141], P,S- [142], and C,S-ligands [143] or changing the substituents on Cp* [144], but from our knowledge this is the first time in which it is brought to light that every atom of ancillary ligand plays a specific role in the reactivity. Eight half sandwich Iridium complexes have been studied in order to clarify the differences in their biological behaviour and in the mode of binding with DNA and BSA.…”

pH-Responsive Release of Ruthenium Metallotherapeutics from Mesoporous Silica-Based Nanocarriers

“…Some of the recent research activities have been dedicated to the development of ruthenium cancer therapeutics [27][28][29]. Ruthenium(II) arene complexes typically designated as [Ru(η 6 -arene)(L)X] n+ , where, beside arene components, a labile leaving group X (usually chlorido ligand) and L an auxiliary bidentate ligand, have been evaluated against a wide range of cancer cells [30][31][32][33][34]. Ru(II) arenes could also be engaged as radiosensitizers for the treatment of colorectal cancer in radiotherapy [35].…”